Skip to main content

SINTX Technologies, Inc.

corporate_fare Company Profile

SINTX Technologies, Inc.

SINT·NASDAQ·Life Sciences·CIK 0001269026

SINTX Technologies is an advanced ceramics company formed in December 1996 that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies. The company provides biomedical solutions specializing in silicon nitride (Si₃N₄) for musculoskeletal and antipathogenic applications. SINTX also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. SINTX is a global leader in silicon nitride research, development, and manufacturing, with products implanted in humans since 2008. SINTX's core business focuses on medical grade silicon nitride for biomedical applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and demonstrate superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans since 2008 in the U.S., Europe, South America, and Asia. This established use, along with resistance to bacterial adhesion and bone affinity, suggests suitability for other fusion device applications like arthroplasty implants, foot wedges, and dental implants. In October 2025, SINTX received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System, enabling commercial entry into reconstructive foot and ankle surgery in the United States. SINTX silicon nitride products can be polished for articulating applications, such as bearings for hip and knee replacements.

SINTX Technologies, Inc. (NASDAQ:SINT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for SINT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • First Human Surgery Performed with SINTX's FDA-Cleared SINAPTIC® Foot & Ankle Implant
  • Sintx Technologies Appoints Ryan Elmore as President; CEO Eric Olson Retains Chairman Role

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.02M
Net Income
-$10.36M
Diluted EPS
-$6.16
Op. Cash Flow
-$8.57M
Free Cash Flow
-$8.76M
Gross Profit
$461K
Operating Income
-$10.72M
Cash & Equivalents
$4.14M
Total Debt
$7K
Debt / Equity
0.00×
Net Margin
-10.18×
Shares Outstanding
3.97M sh
Source: 10-K · filed 2026-03-20 · accession 0001493152-26-011924
$1.12 -5.08% today
52-week range · as of 2026-11-05 $1.12 – $4.46
Market cap
$8.31M
Volume
39K (1.2× avg)
3-mo avg 32.1K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SINT - Filings & News (Page 2)

SINT
Mar 19, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $1.12 info
Change: -$1.43 (-56%) info
Market Cap: $8.314M info
SINT
Feb 18, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.05
Real-time Price: $1.12 info
Change: -$1.93 (-63%) info
Market Cap: $8.314M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets